What is the 13F Pro Quality Score for ENGN?

13F Pro ranks enGene Therapeutics Inc. (ENGN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ENGN's current score at https://13fpro.ai/research/ENGN (free sign-up required for the full ranking).

Which hedge funds own the most ENGN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ENGN include FCPM III SERVICES B.V., PERCEPTIVE ADVISORS, Siren, L.L.C.. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ENGN as soon as new 13F filings post.

Where does 13F Pro source ENGN data?

All enGene Therapeutics Inc. fundamentals and ownership data come directly from SEC EDGAR. enGene Therapeutics Inc. files with the SEC under CIK 1980845. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ENGN in?

enGene Therapeutics Inc. (ENGN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ENGN research updated on 13F Pro?

ENGN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

enGene Therapeutics Inc.(ENGN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1980845 ENGN stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ENGN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for enGene Therapeutics Inc. (ENGN), a Healthcare sector company. ENGN is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), enGene Therapeutics Inc. reports net income of $-30.2M, free cash flow of $-30.6M. Top institutional holders of ENGN by reported 13-F value include FCPM III SERVICES B.V., PERCEPTIVE ADVISORS, Siren, L.L.C., based on the most recent SEC filings. ENGN trades on the Nasdaq exchange and files with the SEC under CIK 1980845. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ENGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for enGene Therapeutics Inc. directly from SEC EDGAR.

Net Income

Q2 2026

$-30.2M

Free Cash Flow

Q2 2026

$-30.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-112.7% YoY

$-117.3MFY 2025

FY22 $-24.5MFY23 $-99.9MFY24 $-55.1MFY25 $-117.3M

Operating Income

-97.7% YoY

$-123.2MFY 2025

FY22 $-19.4MFY23 $-26.1MFY24 $-62.3MFY25 $-123.2M

EPS (Diluted)

+56.8% YoY

$2.29FY 2025

FY22 $22.15FY23 $75.61FY24 $1.46FY25 $2.29

Total Assets

-28.8% YoY

$221.5MFY 2025

FY22 $23.9MFY23 $87.0MFY24 $311.2MFY25 $221.5M

Op. Cash Flow

-105.5% YoY

$-99.2MFY 2025

FY22 $-17.6MFY23 $-24.7MFY24 $-48.3MFY25 $-99.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Income	$-117.3M -112.7%	$-55.1M +44.8%	$-99.9M -308.5%	$-24.5M	—
Operating Income	$-123.2M -97.7%	$-62.3M -139.1%	$-26.1M -34.1%	$-19.4M	—
EPS (Diluted)	$2.29 +56.8%	$1.46 -98.1%	$75.61 +241.4%	$22.15	—
Total Assets	$221.5M -28.8%	$311.2M +257.8%	$87.0M +263.7%	$23.9M	—
Operating Cash Flow	$-99.2M -105.5%	$-48.3M -95.1%	$-24.7M -40.6%	$-17.6M	—

AI Insight: ENGN Financial Trends

enGene is a pre-revenue biotech with accelerating losses and volatile equity, signaling capital burn and dilution risk.

• Operating losses widened from $17M in Q3 2024 to $32M in Q2 2026, a 88% deterioration over 18 months.

• Operating cash burn averaged $24M per quarter in 2025–2026, with no material improvement or revenue offset.

• Equity swung from $201M low (Q3 2025) to $282M (Q1 2026), reflecting likely dilutive financing and cash depletion.

⚠ Cash runway unclear; $282M equity in Q1 2026 may last <3 years at current $30M quarterly burn without revenue.

⚠ Q1 2026 equity spike suggests capital raise; monitor dilution impact and cash balance disclosures in upcoming filings.

AI Insight: ENGN Ratio Trends

enGene remains deeply unprofitable with shareholder returns deteriorating across all metrics; Q4 2025 marked a nadir with ROE at -90.3% before partial recovery in Q1–Q2 2026.

• ROE collapsed to -90.3% in Q4 2025, then improved to -47.4% by Q2 2026, but remains catastrophically negative.

• ROA and ROIC follow identical trajectory: Q4 2025 worst (-68.4% and -94.2%), partial recovery by Q2 2026 (-39.3% and -50.1%).

• TTM ROIC at -52.0% reflects trailing-twelve-month losses consuming all capital deployed; no path to profitability visible.

⚠ Q4 2025 loss spike unprecedented in dataset; monitor whether Q1–Q2 2026 recovery reflects genuine improvement or one-time seasonal/accounting effects.

⚠ All profitability metrics remain deeply negative; cash burn trajectory critical to assess runway and funding needs.

Get alerted when ENGN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for enGene Therapeutics Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ENGN

FCPM III SERVICES B.V.
$65.6M9,632,561 sh
PERCEPTIVE ADVISORS LLC
$39.7M5,827,506 sh
Siren, L.L.C.
$35.8M5,253,159 sh
VR Adviser, LLC
$32.5M4,771,414 sh
Blue Owl Capital Holdings LP
$30.1M4,416,353 sh
Deep Track Capital, LP
$29.8M4,377,572 sh
BRAIDWELL LP
$16.7M2,456,870 sh
Nextech Invest, Ltd.
$15.8M2,324,943 sh
Vestal Point Capital, LP
$14.7M2,165,000 sh
MPM BioImpact LLC
$12.6M1,845,373 sh

Fund	Value	Shares
FCPM III SERVICES B.V.	$65.6M	9,632,561
PERCEPTIVE ADVISORS LLC	$39.7M	5,827,506
Siren, L.L.C.	$35.8M	5,253,159
VR Adviser, LLC	$32.5M	4,771,414
Blue Owl Capital Holdings LP	$30.1M	4,416,353
Deep Track Capital, LP	$29.8M	4,377,572
BRAIDWELL LP	$16.7M	2,456,870
Nextech Invest, Ltd.	$15.8M	2,324,943
Vestal Point Capital, LP	$14.7M	2,165,000
MPM BioImpact LLC	$12.6M	1,845,373

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ENGN on your watchlist

Track score changes the day enGene Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ENGN a good stock to buy?

13F Pro's AI-powered analysis of enGene Therapeutics Inc. (ENGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ENGN are available on the ENGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ENGN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ENGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of enGene Therapeutics Inc.'s investment landscape.